171 related articles for article (PubMed ID: 21544715)
1. Discovery of an orally available PAR-1 antagonist as a novel antiplatelet agent.
Lee S
Arch Pharm Res; 2011 Apr; 34(4):515-7. PubMed ID: 21544715
[TBL] [Abstract][Full Text] [Related]
2. Vascular PAR-1: activity and antagonism.
Lang NN; Guðmundsdóttir IJ; Newby DE
Cardiovasc Ther; 2011 Dec; 29(6):349-61. PubMed ID: 20528879
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial.
Morrow DA; Scirica BM; Fox KA; Berman G; Strony J; Veltri E; Bonaca MP; Fish P; McCabe CH; Braunwald E;
Am Heart J; 2009 Sep; 158(3):335-341.e3. PubMed ID: 19699854
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of action and clinical development of platelet thrombin receptor antagonists.
Ueno M; Ferreiro JL; Angiolillo DJ
Expert Rev Cardiovasc Ther; 2010 Aug; 8(8):1191-200. PubMed ID: 20670195
[TBL] [Abstract][Full Text] [Related]
5. G-protein-coupled receptors as signaling targets for antiplatelet therapy.
Smyth SS; Woulfe DS; Weitz JI; Gachet C; Conley PB; Goodman SG; Roe MT; Kuliopulos A; Moliterno DJ; French PA; Steinhubl SR; Becker RC;
Arterioscler Thromb Vasc Biol; 2009 Apr; 29(4):449-57. PubMed ID: 19023091
[TBL] [Abstract][Full Text] [Related]
6. Thrombin receptor antagonism -the potential of antiplatelet medication SCH 530348.
Macaulay TE; Allen C; Ziada KM
Expert Opin Pharmacother; 2010 Apr; 11(6):1015-22. PubMed ID: 20307225
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis.
Jennings LK
Thromb Haemost; 2009 Aug; 102(2):248-57. PubMed ID: 19652875
[TBL] [Abstract][Full Text] [Related]
8. Protease-activated receptor-1 antagonists: focus on SCH 530348.
Sugunaraj JP; Mehta V; Kalra A; Sukhija R; Palaniswamy C
Am J Ther; 2012 Nov; 19(6):465-9. PubMed ID: 21248619
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel protease activated receptors 1 antagonists with potent antithrombotic activity in vivo.
Perez M; Lamothe M; Maraval C; Mirabel E; Loubat C; Planty B; Horn C; Michaux J; Marrot S; Letienne R; Pignier C; Bocquet A; Nadal-Wollbold F; Cussac D; de Vries L; Le Grand B
J Med Chem; 2009 Oct; 52(19):5826-36. PubMed ID: 19791800
[TBL] [Abstract][Full Text] [Related]
10. Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease.
Chintala M; Shimizu K; Ogawa M; Yamaguchi H; Doi M; Jensen P
J Pharmacol Sci; 2008 Dec; 108(4):433-8. PubMed ID: 19098390
[TBL] [Abstract][Full Text] [Related]
11. Platelet biology and implications for antiplatelet therapy in atherothrombotic disease.
Montalescot G
Clin Appl Thromb Hemost; 2011 Aug; 17(4):371-80. PubMed ID: 20566574
[TBL] [Abstract][Full Text] [Related]
12. Tailoring naringenin conjugates with amplified and triple antiplatelet activity profile: Rational design, synthesis, human plasma stability and in vitro evaluation.
Stylos E; Chatziathanasiadou MV; Tsiailanis A; Kellici TF; Tsoumani M; Kostagianni AD; Deligianni M; Tselepis AD; Tzakos AG
Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt A):2609-2618. PubMed ID: 28844979
[TBL] [Abstract][Full Text] [Related]
13. Improving antiplatelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1.
Hildemann SK; Bode C
Hamostaseologie; 2009 Nov; 29(4):349-55. PubMed ID: 19882073
[TBL] [Abstract][Full Text] [Related]
14. SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis.
Oestreich J
Curr Opin Investig Drugs; 2009 Sep; 10(9):988-96. PubMed ID: 19705342
[TBL] [Abstract][Full Text] [Related]
15. Vorapaxar: a novel protease-activated receptor-1 inhibitor.
Gurbel PA; Jeong YH; Tantry US
Expert Opin Investig Drugs; 2011 Oct; 20(10):1445-53. PubMed ID: 21819272
[TBL] [Abstract][Full Text] [Related]
16. PAR-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosis.
Leonardi S; Becker RC
Handb Exp Pharmacol; 2012; (210):239-60. PubMed ID: 22918734
[TBL] [Abstract][Full Text] [Related]
17. New antiplatelet agents.
Spectre G; Varon D
Curr Opin Hematol; 2009 Sep; 16(5):365-70. PubMed ID: 19587588
[TBL] [Abstract][Full Text] [Related]
18. Challenges and promises of developing thrombin receptor antagonists.
Yang J; Xu K; Seiffert D
Recent Pat Cardiovasc Drug Discov; 2010 Nov; 5(3):162-70. PubMed ID: 20874673
[TBL] [Abstract][Full Text] [Related]
19. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.
Serebruany VL; Kogushi M; Dastros-Pitei D; Flather M; Bhatt DL
Thromb Haemost; 2009 Jul; 102(1):111-9. PubMed ID: 19572075
[TBL] [Abstract][Full Text] [Related]
20. SCH 530348: a novel oral thrombin receptor antagonist.
Bonaca MP; Morrow DA
Future Cardiol; 2009 Sep; 5(5):435-42. PubMed ID: 19715408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
